These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 37957561)
21. Predictive Risk Models to Identify Patients at High-Risk for Severe Clinical Outcomes With Chronic Kidney Disease and Type 2 Diabetes. Sheer R; Nair R; Pasquale MK; Evers T; Cockrell M; Gay A; Singh R; Schmedt N J Prim Care Community Health; 2022; 13():21501319211063726. PubMed ID: 35068244 [TBL] [Abstract][Full Text] [Related]
22. Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants. Olufade T; Lamerato L; Sánchez JJG; Jiang L; Huang J; Nolan S; Rangaswami J Adv Ther; 2021 Feb; 38(2):1352-1363. PubMed ID: 33474707 [TBL] [Abstract][Full Text] [Related]
23. Heart failure hospitalisation relative to major atherosclerotic events in type 2 diabetes with versus without chronic kidney disease: A meta-analysis of cardiovascular outcomes trials. Sacre JW; Magliano DJ; Shaw JE Diabetes Metab; 2021 Sep; 47(5):101249. PubMed ID: 33744399 [TBL] [Abstract][Full Text] [Related]
24. Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease. Bansal N; Zelnick L; Bhat Z; Dobre M; He J; Lash J; Jaar B; Mehta R; Raj D; Rincon-Choles H; Saunders M; Schrauben S; Weir M; Wright J; Go AS; J Am Coll Cardiol; 2019 Jun; 73(21):2691-2700. PubMed ID: 31146814 [TBL] [Abstract][Full Text] [Related]
25. Estimated health economic impact of conducting urine albumin-to-creatinine ratio testing alongside estimated glomerular filtration rate testing in the early stages of chronic kidney disease in patients with type 2 diabetes. Rossing P; Groehl F; Mernagh P; Folkerts K; Garreta-Rufas A; Harris J; Meredith K; Carter M; Åkerborg Ö; Wanner C; Hobbs FDR J Med Econ; 2023; 26(1):935-943. PubMed ID: 37439218 [TBL] [Abstract][Full Text] [Related]
26. Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults. Schechter M; Melzer Cohen C; Yanuv I; Rozenberg A; Chodick G; Bodegård J; Leiter LA; Verma S; Lambers Heerspink HJ; Karasik A; Mosenzon O Cardiovasc Diabetol; 2022 Jun; 21(1):104. PubMed ID: 35689214 [TBL] [Abstract][Full Text] [Related]
27. Prevalence and coprevalence of chronic comorbid conditions in patients with type 2 diabetes in Catalonia: a population-based cross-sectional study. Mata-Cases M; Franch-Nadal J; Real J; Cedenilla M; Mauricio D BMJ Open; 2019 Oct; 9(10):e031281. PubMed ID: 31662386 [TBL] [Abstract][Full Text] [Related]
28. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. Pitt B; Filippatos G; Agarwal R; Anker SD; Bakris GL; Rossing P; Joseph A; Kolkhof P; Nowack C; Schloemer P; Ruilope LM; N Engl J Med; 2021 Dec; 385(24):2252-2263. PubMed ID: 34449181 [TBL] [Abstract][Full Text] [Related]
29. Prevalence of chronic kidney disease in the community using data from OxRen: a UK population-based cohort study. Hirst JA; Hill N; O'Callaghan CA; Lasserson D; McManus RJ; Ogburn E; Mena JMO; Shine B; Taylor CJ; Vazquez-Montes MD; Yang Y; Hobbs FR Br J Gen Pract; 2020 Apr; 70(693):e285-e293. PubMed ID: 32041766 [TBL] [Abstract][Full Text] [Related]
30. Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial. Kalantar-Zadeh K; Schwartz GG; Nicholls SJ; Buhr KA; Ginsberg HN; Johansson JO; Kulikowski E; Lebioda K; Toth PP; Wong N; Sweeney M; Ray KK; Clin J Am Soc Nephrol; 2021 May; 16(5):705-716. PubMed ID: 33906908 [TBL] [Abstract][Full Text] [Related]
31. Ethnic Disparities in CKD in the Netherlands: The Healthy Life in an Urban Setting (HELIUS) Study. Agyemang C; Snijder MB; Adjei DN; van den Born BJ; Modesti PA; Peters RJ; Stronks K; Vogt L Am J Kidney Dis; 2016 Mar; 67(3):391-9. PubMed ID: 26342454 [TBL] [Abstract][Full Text] [Related]
32. Patients with type 1 and type 2 diabetes hospitalized with COVID-19 in comparison with influenza: mortality and cardiorenal complications assessed by nationwide Swedish registry data. Kristófi R; Bodegard J; Ritsinger V; Thuresson M; Nathanson D; Nyström T; Norhammar A; Eriksson JW Cardiovasc Diabetol; 2022 Dec; 21(1):282. PubMed ID: 36522650 [TBL] [Abstract][Full Text] [Related]
33. The Bidirectional Association of Chronic Kidney Disease, Type 2 Diabetes, Atherosclerotic Cardiovascular Disease, and Heart Failure: The Cardio-Renal-Metabolic Syndrome. Nichols GA; Amitay EL; Chatterjee S; Steubl D Metab Syndr Relat Disord; 2023 Jun; 21(5):261-266. PubMed ID: 37130317 [No Abstract] [Full Text] [Related]
34. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL; Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413 [TBL] [Abstract][Full Text] [Related]
35. Cardiovascular and renal diseases in type 2 diabetes patients: 5-year cumulative incidence of the first occurred manifestation and hospitalization cost: a cohort within the French SNDS nationwide claims database. Blin P; Joubert M; Jourdain P; Zaoui P; Guiard E; Sakr D; Dureau-Pournin C; Bernard MA; Lassalle R; Thomas-Delecourt F; Bineau S; Moore N; Droz-Perroteau C Cardiovasc Diabetol; 2024 Jan; 23(1):22. PubMed ID: 38195491 [TBL] [Abstract][Full Text] [Related]
36. High prevalence of chronic kidney disease in Finnish patients with type 2 diabetes treated in primary care. Metsärinne K; Bröijersen A; Kantola I; Niskanen L; Rissanen A; Appelroth T; Pöntynen N; Poussa T; Koivisto V; Virkamäki A; Prim Care Diabetes; 2015 Feb; 9(1):31-8. PubMed ID: 25066820 [TBL] [Abstract][Full Text] [Related]
37. Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. Ferreira JP; Girerd N; Pellicori P; Duarte K; Girerd S; Pfeffer MA; McMurray JJ; Pitt B; Dickstein K; Jacobs L; Staessen JA; Butler J; Latini R; Masson S; Mebazaa A; Rocca HP; Delles C; Heymans S; Sattar N; Jukema JW; Cleland JG; Zannad F; Rossignol P; BMC Med; 2016 Nov; 14(1):181. PubMed ID: 27829460 [TBL] [Abstract][Full Text] [Related]
38. Development of clinical prediction models for renal and cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease using time-varying predictors. Ye W; Ding X; Putnam N; Farej R; Singh R; Wang D; Kuo S; Kong SX; Elliott JC; Lott J; Herman WH J Diabetes Complications; 2022 May; 36(5):108180. PubMed ID: 35339377 [TBL] [Abstract][Full Text] [Related]
39. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases. Komuro I; Kadowaki T; Bodegård J; Thuresson M; Okami S; Yajima T Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():19-27. PubMed ID: 33835641 [TBL] [Abstract][Full Text] [Related]
40. Chronic kidney disease prevalence and cardiovascular risk in a cohort of patients with type 2 diabetes followed for 10 years in Badajoz (Spain). An observational study. Calvo-Hueros JI; Martín-Hidalgo-Barquero MV; Morales-Gabardino JA; Buitrago F Prim Care Diabetes; 2021 Apr; 15(2):391-396. PubMed ID: 33323354 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]